Figure 3.

Targeting EGFR in IECs of established tumors does not lead to tumor shrinkage. (A) Scheme of inducible EGFR deletion in the AOM/DSS model. Villin-CreER^T2 activation was mediated by tamoxifen injection after tumors had developed. (B) Western blot confirming loss of EGFR expression in purified colonocytes from Egfr^ΔIEC-ER mice on Cre induction. (C–E) Analysis of tumor growth in Egfr^ΔIEC-ER mice and controls (n = 7–8) treated with tamoxifen showing (C) tumor area, (D) load, and (E) multiplicity.